VC  Mission Bay Capital

     Office Locations:

1700 4th Street, Suite 214
San Francisco, CA 94158
Phone: 415-240-4970



  • Early



  • Life Sciences & Healthcare



    Mission Bay Capital is an independent venture firm focused on making pivotal, early-stage investments in bioscience companies emerging from the University of California. Founded in June 2009, Mission Bay Capital is fueling breakthrough bioscience technologies to meet society's challenges while also helping to boost the California economy. Mission Bay Capital is managed by Regis Kelly, PhD, and Douglas Crawford, PhD, who jointly serve as managing directors of the fund in a pro-bono capacity, and are dedicated to promoting cross-disciplinary and cross-campus research within QB3 (see profile). The $7.5 million Mission Bay Capital Fund will be invested in companies whose founders or technologies are associated with the University of California system. In addition to bringing needed products and companies to fruition, MBC will return 20% of its profit to the University of California to populate subsequent MBC funds and provide an endowment for QB3. Limited partners in the fund include Pfizer Inc.; John Wadsworth, Jr., of Manitou Ventures; and law firm Wilson Sonsini Goodrich & Rosati Investments, among others.



      Fund Name



    Get funds under management for this firm including Fund name, Dollar size of fund raise, and Vintage with a National Database subscription or Silicon Valley Database subscription.

    Investment Firm Key

       VC = Venture Capital
       PE = Private Equity
       A = Angel
       I = Incubator
       MB = Merchant Bank
       VD = Venture Debt
       FI = Family Investment Office
       FOF = Fund of Funds
       ED = Economic Development Office   
       TT = Technology Transfer Office
       CVC = Corporate Venture Capital
       SEC = Secondary Purchaser
       HF = Hedge Fund/Mutual Fund
    Venture Capital
    Seed Stage
    (includes "pre-seed," or
    concept stage)
    No Revenue
    Early StageMinimal
    Growth Stage
    (also called Mid-stage)
    Expansion Stage
    (also called Late-stage)
    $7M and greater
    Private Equity
    Lower Middle Market$10M-$249M
    Middle Market$250M-$499M
    Upper Middle Market$500M-$1B
    Large Cap>$1B

    Investment Team:

    Name   Title
    Get the complete investment team + individual email addresses for investment team partners. Get personal images, LinkedIn links, investment specialties, office locations and more with a National Database subscription or Silicon Valley Database subscription.
    Douglas Crawford Ph.D. Managing Partner
    Neena Kadaba Ph.D. Partner
    Regis B. Kelly Ph.D. Managing Partner


    Recent Funding Events (trailing 12 months):







      Wild Type





      ViewPoint Therapeutics



      Series B


    Portfolio companies include:

        web link

        web link

      Bolt Threads
        web link

        web link

      Caribou Biosciences
        web link

      Circle Pharma
        web link

      Effector Therapeutics
        web link

        web link

        web link

        web link

      Ocular Dynamics
        web link

      Pionyr Immunotherapeutics
        web link

        web link

      Redwood Bioscience
        web link

      Refactored Materials
        web link

      SiteOne Therapeutics
        web link

      Symic Biomedical
        web link

      ViewPoint Therapeutics
        web link

      Wild Type
        web link

      Zephyrus Biosciences
        web link

        web link


    Recent News: